ClearPoint Neuro CFO exercises 32,627 RSUs

ClearPoint Neuro Chief Financial Officer Danilo D'Alessandro settled 32,627 restricted stock units into an equal number of shares of common stock on their scheduled vesting date.

Rhea-AI Filing Summary

ClearPoint Neuro Chief Financial Officer Danilo D'Alessandro settled 32,627 restricted stock units into an equal number of shares of common stock on their scheduled vesting date.

Of these, 16,601 shares were delivered back to ClearPoint Neuro at $11.53 per share to cover tax withholding, leaving him with 102,684 shares of common stock held directly.

Insights

Equity compensation analyst

CFO’s RSU vesting and tax withholding look like routine equity compensation activity.

The ClearPoint Neuro Chief Financial Officer, Danilo D'Alessandro, converted 32,627 restricted stock units into common shares as they vested. This is coded as a derivative exercise and reflects previously granted equity turning into regular stock rather than an open-market purchase.

To satisfy tax obligations from the vesting, 16,601 shares were delivered back to the company at $11.53 per share. After these transactions, he directly owns 102,684 common shares. Because the disposition is strictly for tax withholding, it carries minimal signaling value about his view of the stock.

Insider Trade Summary

32,627 shares exercised/converted

Exercise 3 txns

Insider D'Alessandro Danilo

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	32,627	$0.00	$0.00
Exercise	Common Stock	32,627	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	16,601	$11.53	$191K

Holdings After Transaction: Restricted Stock Units — 32,626 contracts (Direct); Common Stock — 102,684 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
2. F2. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ClearPoint Neuro (CLPT) CFO report in this insider transaction?

ClearPoint Neuro’s CFO, Danilo D'Alessandro, reported vesting of 32,627 restricted stock units that settled into the same number of common shares. This represents conversion of prior equity awards into stock, not an open-market share purchase or sale.

How many ClearPoint Neuro shares did the CFO use to cover taxes?

The CFO delivered 16,601 shares of common stock to ClearPoint Neuro to satisfy tax withholding obligations at $11.53 per share. These shares cover income taxes triggered by the vesting of restricted stock units, rather than representing a discretionary market sale.

How many ClearPoint Neuro (CLPT) shares does the CFO own after these transactions?

Following the RSU settlement and tax withholding, the CFO directly holds 102,684 shares of ClearPoint Neuro common stock. This figure reflects his position after 16,601 shares were delivered back to the company to cover the tax obligations from the vesting event.

Was the ClearPoint Neuro CFO’s Form 4 activity an open-market trade?

No, the reported activity reflects RSU vesting and tax withholding, not open-market buying or selling. Shares were issued from vested restricted stock units and some were delivered back to ClearPoint Neuro to pay taxes, a standard equity compensation mechanism.

What price was used for the ClearPoint Neuro CFO’s tax-withholding shares?

The 16,601 shares delivered for tax withholding were valued at $11.53 per share. This value determines how many shares were needed to satisfy the CFO’s tax liability resulting from the vesting of his restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/16/2026 - 02:53 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

D'Alessandro Danilo

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		M		32,627	A	(1)	119,285	D
Common Stock	03/12/2026		F		16,601(2)	D	$11.53	102,684	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/12/2026		M			32,627	(1)	(1)	Common Stock	32,627	(1)	32,626	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

2. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

	/s/ Danilo D'Alessandro	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.